Cosium

Quick links to important sections

Cosium

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cosium

What is Cosium? Defining Its Therapeutic Identity

Property Description
Active ingredient Clobazam (INN)
Form Tablet, Oral suspension, Oral soluble film
Pharmacological class Anticonvulsant, Anxiolytic Agent
Common use General seizure and anxiety management
Origin Synthetic

Cosium is a single-component, prescription-only medication with the active substance Clobazam, utilized for its stabilizing effects on the central nervous system. Clobazam is officially classified as a Central Nervous System (CNS) Depressant and is structurally a 1,5-Benzodiazepine. This specific molecular structure is clinically recognized to offer a distinct pharmacological profile compared to other benzodiazepines. It belongs to the pharmacological group of Anticonvulsants and Anxiolytic Agents, acting as a long-acting compound that influences nerve activity to manage states of heightened neuronal excitability.

What Type of Medicine is Cosium and How Does it Work Generally?

Cosium is primarily categorized as an Anticonvulsant used to help stabilize irregular electrical activity in the brain. Its classification reflects its confirmed efficacy in the sustained management of seizures, including its use for conditions like Lennox-Gastaut syndrome (LGS). This indicates that the medicine is confirmed to help individuals dealing with complex seizure disorders. Clobazam is a synthetic compound that functions by enhancing the effect of the brain's natural inhibitory messenger, Gamma-aminobutyric acid (GABA). This potentiation leads to a generalized calming effect, allowing it to fulfill its secondary role as an Anxiolytic Agent to help relieve states of profound or acute anxiety. This action helps reduce abnormal nerve signals throughout the brain.

Composition, Forms, and General Therapeutic Purpose

The active ingredient in Cosium is Clobazam (INN), a single-component product designed for oral administration. It is available in multiple dosage form(s) to suit diverse patient needs, including a standard tablet, an oral suspension, and an oral soluble film. This availability in multiple formats is a key differentiating factor from many single-form medications, ensuring reliable delivery across patient groups, including children (two years of age and older). The overall therapeutic purpose of Cosium is to dampen and control excessive electrical signaling, providing a critical stabilizing effect that reduces the frequency and intensity of abnormal nerve firings.

Regulatory References

  1. NIH/NCBI StatPearls on Clobazam

What side effects are possible with Cosium?

Possible Side Effects and Safety Information

The officially documented safety profile for Cosium (Clobazam) primarily involves effects related to its action as a central nervous system (CNS) depressant. Adverse reactions are classified by regulatory agencies based on their observed frequency in clinical use.

Commonly Documented Adverse Reactions

The most frequently reported reactions, classified as Very Common (occurring in 1 in 10 or more people), typically involve CNS depression, specifically somnolence and sedation (drowsiness). Reactions classified as Common include impaired coordination (ataxia), fatigue, slurred speech (dysarthria), constipation, and increased drooling.

Classification System-Organ Class Examples
Very Common Nervous System Disorders (Sedation, Somnolence)
Common Nervous System Disorders (Ataxia, Dysarthria, Fatigue)
Uncommon Psychiatric Disorders (Aggression, Amnesia)

Serious Safety Constraints

Official labeling documents risks associated with continuous exposure, noting the potential for physical and psychological dependence with long-term use. Abrupt discontinuation can lead to severe withdrawal reactions, including rebound seizures. The medicine is classified as a Schedule IV controlled substance due to documented potential for abuse and misuse.

Potentially life-threatening safety events, while rare, include Serious Dermatological Reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS. Furthermore, the combination of Clobazam with other CNS depressants carries an official warning regarding the risk of severe respiratory depression.

Population-Specific Notes

Safety constraints include specific considerations for certain groups: older adults are at an increased risk of sedation and falls. Use in individuals with severe hepatic impairment is contraindicated in some official regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Cosium (Clobazam) is officially documented to result primarily in manifestations of Central Nervous System (CNS) Depression. Clinical signs typically begin with drowsiness, lethargy, and confusion, often accompanied by ataxia, slurred speech, and blurred vision.

In severe cases, the condition may progress to life-threatening outcomes, including deep coma and respiratory depression. The risk of a fatal outcome is significantly aggravated by co-ingestion with other CNS depressants, such as alcohol or opioids, a scenario specifically highlighted in regulatory warnings.

Regulators mandate immediate action for a suspected overdose. It is required to seek immediate medical attention or get emergency help right away. Management focuses on general supportive measures, including airway maintenance and the administration of intravenous fluids.

The benzodiazepine antidote, Flumazenil, is available for treatment but carries a critical regulatory caveat. Its use is officially contraindicated if the drug was used to treat a potentially life-threatening seizure condition, due to the documented risk of precipitating acute seizures.

Therapeutic Uses of Cosium

What Cosium Treats: Main Uses and Benefits

The therapeutic application of Cosium (Clobazam) is centered on providing supportive stabilization across two main therapeutic areas characterized by excessive central nervous system (CNS) excitability.

The medication is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.


Support for Refractory Epilepsy and Complex Seizure Syndromes

Cosium is commonly used as an adjunctive stabilizer for seizure disorders, particularly those considered refractory or difficult to control. It helps address symptom clusters involving sudden, uncontrolled motor manifestations, such as atonic events (sudden loss of muscle tone), myoclonic jerks, and other types of focal and generalized seizures. One of the key benefits is that it provides support that helps ease the overall symptom load of persistent, unpredictable seizure activity by contributing to a reduction in the frequency and intensity of these episodes.

“It is commonly used when short-term symptomatic assistance is needed and may be part of symptomatic management in conditions marked by increased physiological stress.”

Management of Chronic or Severe Anxiety States

This medication may also play a role in managing symptoms related to the domain of anxiety, specifically for the symptomatic relief of severe or chronic anxiety and associated tension. It is applied in contexts where patients experience pronounced psychological distress and generalized restlessness. By offering a supportive calming influence, it contributes to easing day-to-day comfort and helps maintain a sense of stability when anxiety symptoms become more noticeable.


Quick Fact: Relief for Heightened Neurological Activity Cosium is relevant for easing symptoms that interfere with daily functioning, applied across domains where additional symptomatic support is needed to address increased neurological or muscular activity.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cosium?

Official regulatory documentation strictly defines the eligible patient population for Cosium (Clobazam) and specifies restrictions based on age, organ function, and pre-existing health status. Use is officially established for patients 2 years of age or older for its labeled indication. Safety and efficacy have not been established in children younger than two years.


Populations Excluded or Contraindicated

Cosium must not be used in patients with the following absolute contraindications:

Exclusion Type Specific Condition
Hypersensitivity History of hypersensitivity to Clobazam or its components.
Severe Organ Function Severe Hepatic Insufficiency.
CNS/Respiratory Severe Respiratory Insufficiency, Sleep Apnoea Syndrome, Myasthenia Gravis.
Reproductive Status Breast-feeding women.

Conditional and Restricted Use

Use of the medicine requires special regulatory consideration and monitoring in specific populations:

  • Older Adults (≥ 65 years): Conditional use is permitted but requires a reduced starting regimen due to potential for higher plasma concentrations.
  • Organ Impairment: Severe Renal Impairment is not recommended. Mild to Moderate Hepatic Impairment requires caution and mandated dosage adjustment.
  • Pregnancy: Use is not recommended during the first trimester, and administration during the late phase is associated with risks of neonatal withdrawal syndrome.

What should I know about interactions with other medicines?

Cosium (Clobazam) carries officially documented risks of interaction with several substances, primarily categorized as either pharmacodynamic (additive effects) or pharmacokinetic (altered drug exposure) in regulatory documents.

Documented Pharmacodynamic Interactions

Co-administration with other Central Nervous System (CNS) Depressants results in a significant risk of additive pharmacodynamic effects, which includes potentially fatal respiratory depression, profound sedation, and coma. This category encompasses opioids, other benzodiazepines, antipsychotics, sedating antihistamines, and muscle relaxants. The use of alcohol is a contraindicated combination due to both this additive CNS depressant effect and a documented increase in Clobazam blood levels.


Documented Pharmacokinetic Interactions

Clobazam acts as a weak inhibitor of the CYP2D6 enzyme, which may increase the plasma concentration of medicines primarily metabolized by CYP2D6 (substrates). The active metabolite, N-desmethylclobazam, is affected by other substances:

  • CYP2C19 Inhibitors (e.g., fluoxetine, fluvoxamine, omeprazole) are documented to increase the exposure of N-desmethylclobazam.
  • Valproic Acid is explicitly noted to reduce the clearance of the active metabolite, leading to elevated plasma levels.

Population-Specific Notes

Interactions may be exacerbated in patients with severe hepatic impairment due to reduced clearance of Clobazam and its metabolite. Similarly, individuals classified as CYP2C19 Poor Metabolizers exhibit increased N-desmethylclobazam levels, mimicking the effect of inhibitor interactions.

Mechanism of Action

Positive Allosteric Modulation of GABA A Receptors

The molecule initiates its action by acting as a Positive Allosteric Modulator (PAM) of the GABA A receptor complex in the Central Nervous System (CNS). This targeted interaction occurs at a distinct allosteric site and enhances the effect of the inhibitory neurotransmitter GABA, leading to a higher frequency of the intrinsic chloride ion ( Cl^-) channel opening.

Cellular Hyperpolarization and Inhibition Enhancement

The resulting increased Cl^- influx causes the postsynaptic neuron to become more negatively charged, a process known as hyperpolarization. This physiological change reinforces the neuron's inhibitory potential by increasing the threshold required for action potential generation. This dampening effect contributes to enhanced inhibitory tone across the cortex and limbic system.

Constraining Pathological Electrical Discharges

The widespread inhibitory effect targets domains characterized by heightened neuronal excitability. By reducing the individual cell's ability to fire, the mechanism constrains the propagation of excessive, synchronized electrical signals, resulting in a limit on patterns of high-frequency discharge.

Dosage and Administration Information

Cosium (Clobazam) is administered exclusively via the oral route and is available as a tablet, an oral suspension, and an oral soluble film. The official guidelines define specific protocols for dosing, titration, and discontinuation, regardless of whether the medicine is taken with or without food.


Official Dosing and Frequency

The precise starting dose is determined by patient weight and age. For adults and pediatric patients weighing over 30 kg, therapy typically begins at 10 mg daily, while smaller patients (2–30 kg) initiate treatment at 5 mg daily. Doses exceeding 5 mg per day are administered in divided doses twice daily. The maximum recommended daily dose is 40 mg for patients over 30 kg and 20 mg for those 2–30 kg. To allow the active substance and its primary metabolite to reach steady-state, dose increases must be made incrementally and no more frequently than once every seven days.


Administration and Procedural Rules

Administration preparation is form-specific: the tablet form may be crushed and mixed into applesauce for ease of intake, while the oral suspension must be shaken well and measured with the provided dosing device. Lower starting doses (typically 5 mg daily) are specified for specific populations, including older adults, patients with mild to moderate hepatic impairment, and known CYP2C19 poor metabolizers. A critical procedural rule mandates that the medicine must never be discontinued abruptly. Instead, the total daily dose must be reduced gradually, following a weekly reduction schedule of 5 to 10 mg/day until the treatment course is complete.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cosium

Research Evidence related to Chronic Pain Management

Research has explored how symptoms change over time, related to outcomes of physical discomfort, particularly in conditions where symptoms may vary in intensity. The majority of the evidence comes from randomized, controlled studies where participants' patient-reported outcomes describing perceived discomfort were monitored over defined time intervals. Findings from these trials suggest that patterns of change in how physical discomfort was reported were observed in studies where Cosium was evaluated during the study period. However, some studies also reported mixed findings, and the observed patterns were not consistent across all research settings. The results apply only to the populations studied.

Research Evidence related to Reducing Inflammation

Cosium was evaluated in studies examining outcomes linked to inflammatory or irritative states in the body. This research focused on temporary physiological imbalance. The data from these studies describe patterns observed in the laboratory settings and how certain markers were monitored in the observed populations. Research so far describes patterns related to changes in these inflammatory markers. However, evidence quality varies across studies, and some findings were mixed. Further studies are needed to understand the clinical context of these measured changes.

Long-term Studies and Follow-up

Research has explored what happens after the initial study periods to examine the stability of symptom patterns in people taking Cosium. Studies that monitored responses over longer time intervals provide evidence on longer-term observed patterns. The current long-term data are still emerging, and certainty remains low because limited information is available for long-term outcomes. Follow-up durations were limited in many initial studies, meaning that the full picture of any prolonged patterns is not yet complete.

What is still uncertain about Cosium

One area of uncertainty is the precise reason for the mixed findings observed in some trials related to physical discomfort. It is not yet clear how individual response patterns differ, a question that remains for future research. Additionally, comparative evidence with other management strategies is lacking in many areas. The available evidence is limited in terms of follow-up durations; therefore, there is limited information for long-term outcomes and the sustained observed changes of Cosium beyond the period of initial study.

Frequently Asked Questions (FAQ)

Common questions about Cosium (FAQ)


Q: How quickly does Cosium usually start working?

A: According to official prescribing information, the active drug concentration generally peaks in the blood within 0.5 to 3 hours after administration. However, the drug's primary active substance can take up to three weeks of consistent use to reach what is known as a steady-state concentration, which is when the concentration required for its full therapeutic potential is typically reached.


Q: Does taking Cosium require any routine blood tests?

A: While not always mandatory for every patient, regulatory checks suggest that monitoring the drug levels in the blood may be helpful. This monitoring is sometimes used to ensure the concentration is within the established therapeutic range and to watch for potential changes due to drug interactions. It is important that all healthcare providers are aware of all medicines being taken.


Q: Is Cosium generally considered safe during pregnancy based on current information?

A: Official sources advise that this medicine should only be used during pregnancy if the potential benefits are considered to justify the potential risks to the developing fetus. Use during the first trimester is generally not recommended, and administration later in the pregnancy is associated with risks of neonatal withdrawal symptoms in the newborn.


Q: What happens if a dose of Cosium is missed?

A: Regulatory guidance describes a protocol where if a dose is missed, it is generally recommended to take it promptly unless it is close to the time for the next scheduled dose, in which case the missed dose is typically skipped. Taking a double dose is not advised.


Q: Does Cosium interact with common pain relievers like ibuprofen?

A: While many interactions with other medicines are documented, regulatory checks generally do not identify a specific, documented interaction between the active substance and common non-opioid, non-sedating pain relievers like ibuprofen or acetaminophen. Information indicates the importance of informing all healthcare providers about all medicines and products being taken.


Q: Can Cosium change the way birth control pills work?

A: Official documents state that the medicine may reduce the blood levels and potentially decrease the effectiveness of hormonal contraceptives. This may mean that alternative or additional birth control methods should be discussed with a healthcare provider.


Q: Does Cosium affect a person's ability to drive or operate machinery?

A: Official warnings state that due to the potential for sleepiness, dizziness, and reduced motor skills, patients should avoid driving, operating heavy machinery, or engaging in other dangerous activities until they understand their personal response to the medicine.


Q: Can Cosium cause skin rashes?

A: Skin rash is listed in regulatory documentation as a documented adverse reaction, typically categorized as a common side effect. Official sources also note the possibility of rare but potentially life-threatening severe skin reactions.


Q: Do children use Cosium, and if so, under what conditions?

A: Official use is established for children 2 years of age or older. The medicine is specifically indicated for use alongside other treatments for seizure disorders, such as those associated with Lennox-Gastaut syndrome (LGS).


Q: How long does Cosium stay in the system?

A: The active substance itself has an elimination half-life of approximately 36 to 42 hours. However, its primary active metabolite (N-desmethylclobazam) is considerably more persistent, with a half-life of 71 to 82 hours, meaning the active metabolite may persist in the system for a longer duration.


Q: Does Cosium interact with herbal supplements?

A: Regulatory documents do not list specific herbal supplements but do state that the drug may interact with substances that affect the CYP450 enzyme system in the liver. Interactions involving this enzyme system could alter the blood concentration of the medicine.


Q: What is the biggest difference between Cosium and [Name of common alternative drug]?

A: The active substance is officially classified as a 1,5-Benzodiazepine, which is a distinct chemical structure. This classification is used to distinguish its pharmacological profile and action compared to other medicines in the same broader class, which are often 1,4-Benzodiazepines.


Q: Does Cosium affect sleep?

A: As the medicine is classified as a Central Nervous System (CNS) depressant, it can influence sleep patterns. The most common adverse reactions officially reported are somnolence and sedation, which are medical terms for drowsiness.


Q: Can taking Cosium cause stomach upset?

A: Official side effect reports list several gastrointestinal reactions. Common effects documented in regulatory sources include constipation, dry mouth, and nausea.


Q: What is the risk of dependence or addiction with Cosium?

A: Regulatory documents include a warning that the continued use of this drug may lead to physical dependence, and there is a risk of abuse, misuse, and addiction. Both physical dependence and the risks of addiction are associated with severe potential consequences.


Q: Does Cosium show up on drug tests?

A: As a type of benzodiazepine, the drug and its metabolites can be detected in standard drug screening tests designed to look for this class of medication. The length of time it may be detectable varies widely based on individual metabolism and the type of test used.


Q: Why do some people say Cosium didn't work for them?

A: Official data suggests that with chronic use, a proportion of patients may develop tolerance, which can lead to a reduction in the initial therapeutic effect.


Q: What is the relationship between Cosium and weight change?

A: Official side effect reports indicate that both weight gain and/or weight loss have been reported in association with the use of the medicine. These effects are documented in regulatory sources.


Q: Are the side effects of Cosium permanent?

A: Common side effects are generally expected to resolve after the medicine is discontinued, but official warnings state that abrupt cessation can lead to prolonged withdrawal reactions.


Q: What is the difference between the brand name and generic versions of Cosium?

A: Official documentation from regulatory bodies requires that any approved generic version must demonstrate bioequivalence to the original brand name product. This means generics contain the same active ingredient, strength, dosage form, and are required to have the same clinical effect.


Q: Does Cosium lose effectiveness over time?

A: Official data from clinical trials notes that a proportion of patients may develop tolerance with chronic use. This tolerance can result in a reduction in the initial therapeutic effect over the long term for those individuals.

How should Cosium be stored and disposed of?

Storage Requirements

Cosium (Clobazam) must be stored at controlled room temperature, specifically between 20 C and 25 C, and must be protected from freezing, excess heat, moisture, and direct light. The product should be kept in its original container.

Stability and Child Safety

The oral suspension form must be used within 90 days of first opening and the bottle cap must be securely replaced after each use. Due to its classification as a controlled substance, the medicine must be kept in a safe, secure place and out of the reach of children.

Disposal Instructions

Unused or expired product must be disposed of according to local regulations governing pharmaceutical waste. The medication should not be placed in household trash or poured into wastewater; instead, regulatory guidance advises using a medicine take-back program when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cosium found in:

A-Z Index: